Vera Therapeutics Stock Performance

VERA Stock  USD 41.76  0.39  0.93%   
On a scale of 0 to 100, Vera Therapeutics holds a performance score of 12. The entity has a beta of 1.66, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vera Therapeutics will likely underperform. Please check Vera Therapeutics' skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Vera Therapeutics' existing price patterns will revert.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Vera Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Vera Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(0.93)
Five Day Return
(2.29)
Year To Date Return
(14.11)
Ten Year Return
263.13
All Time Return
263.13
1
Disposition of 100 shares by Fordyce Marshall of Vera Therapeutics at 51.2 subject to Rule 16b-3
11/21/2025
2
Insider Trading
11/25/2025
3
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
12/05/2025
4
Wells Fargo sees short squeeze ahead here are three stocks to play it - CryptoRank
01/06/2026
5
Vera Therapeutics, Inc. Granted FDA Priority Review For Atacicept
01/15/2026
6
Y Intercept Hong Kong Ltd Takes 1.95 Million Position in Vera Therapeutics, Inc. VERA
01/29/2026
7
Is Vera Therapeutics One of the Best High Short Interest Stocks with Biggest Upside Potential
01/30/2026
8
Acquisition by Brenner Robert of 50000 shares of Vera Therapeutics at 42.74 subject to Rule 16b-3
02/04/2026
9
Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment
02/19/2026
Begin Period Cash Flow45.7 M
Total Cashflows From Investing Activities-425 M

Vera Therapeutics Relative Risk vs. Return Landscape

If you would invest  2,924  in Vera Therapeutics on November 23, 2025 and sell it today you would earn a total of  1,252  from holding Vera Therapeutics or generate 42.82% return on investment over 90 days. Vera Therapeutics is currently generating 0.6801% in daily expected returns and assumes 4.2163% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Vera, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Vera Therapeutics is expected to generate 5.65 times more return on investment than the market. However, the company is 5.65 times more volatile than its market benchmark. It trades about 0.16 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of risk.

Vera Therapeutics Target Price Odds to finish over Current Price

The tendency of Vera Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 41.76 90 days 41.76 
about 60.76
Based on a normal probability distribution, the odds of Vera Therapeutics to move above the current price in 90 days from now is about 60.76 (This Vera Therapeutics probability density function shows the probability of Vera Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.66 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Vera Therapeutics will likely underperform. Additionally Vera Therapeutics has an alpha of 0.5409, implying that it can generate a 0.54 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Vera Therapeutics Price Density   
       Price  

Predictive Modules for Vera Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vera Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
37.5741.7946.01
Details
Intrinsic
Valuation
LowRealHigh
37.5852.0356.25
Details
Naive
Forecast
LowNextHigh
36.5640.7744.99
Details
14 Analysts
Consensus
LowTargetHigh
68.3975.1583.42
Details

Vera Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Vera Therapeutics is not an exception. The market had few large corrections towards the Vera Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vera Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vera Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.54
β
Beta against Dow Jones1.66
σ
Overall volatility
7.07
Ir
Information ratio 0.14

Vera Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vera Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vera Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Vera Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (152.15 M) with profit before overhead, payroll, taxes, and interest of 0.
Vera Therapeutics currently holds about 131.93 M in cash with (134.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Vera Therapeutics has a frail financial position based on the latest SEC disclosures
Over 99.0% of the company outstanding shares are owned by institutional investors
Latest headline from finance.yahoo.com: Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment

Vera Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vera Stock often depends not only on the future outlook of the current and potential Vera Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vera Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding55.3 M
Cash And Short Term Investments640.9 M

Vera Therapeutics Fundamentals Growth

Vera Stock prices reflect investors' perceptions of the future prospects and financial health of Vera Therapeutics, and Vera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vera Stock performance.

About Vera Therapeutics Performance

By analyzing Vera Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Vera Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vera Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vera Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.24)(0.25)
Return On Assets(0.21)(0.22)
Return On Equity(0.30)(0.32)

Things to note about Vera Therapeutics performance evaluation

Checking the ongoing alerts about Vera Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Vera Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (152.15 M) with profit before overhead, payroll, taxes, and interest of 0.
Vera Therapeutics currently holds about 131.93 M in cash with (134.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Vera Therapeutics has a frail financial position based on the latest SEC disclosures
Over 99.0% of the company outstanding shares are owned by institutional investors
Latest headline from finance.yahoo.com: Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment
Evaluating Vera Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Vera Therapeutics' stock performance include:
  • Analyzing Vera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vera Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Vera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Vera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vera Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Vera Therapeutics' stock. These opinions can provide insight into Vera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Vera Therapeutics' stock performance is not an exact science, and many factors can impact Vera Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Vera Stock analysis

When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments